Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (14601)	9/16/2000 3:07:08 PM
From: Cacaito	Respond to of 17367

Rk, your xoma stock profit motive is not important at all when you are making sanctimonious choral calls with blue about the "kids". I do not know more than the xoma scientists, never claimed that, I am just reading their findings, and their equal intelligence and less bias counterparts at the FDA. soon will be a year and there is no sign of baxter backing this one with a big indication. Retrospect? I already have my past chance of getting out, I used to like the drug hope to the point of losing good money after it, I risk I lost , no problem anymore. My problem is the PROSPECT. I am not buying this "other channels". Well, money movers can organized and hype the press and politicians and get an ineffective drug in the market, maybe it has happen in the past, is that the goal now?

To: Robert K. who wrote (14601)	9/16/2000 3:21:12 PM
From: Cacaito	Respond to of 17367

Rk, you were the main defender of the bpi trauma possibilities a year ago, claiming many of the same claims made now for the meningo case. I said it was dead, Gw said the unexpected "good placebo group" different cheese same rat. READ it from xoma web site now: "We do not plan to pursue the trauma indication further." Retrospect?

To: Robert K. who wrote (14601)	9/16/2000 3:41:46 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Bpi chances in meningococcemia indication? yes, if a larger trail confirms what this one showed as a trend to decrease amputations. If xoma loves the kids, as much as you and blue, they could go ahead and do a 900 subjects $150M study with a clearcut goal to decrease amputations, to get the definite answer, like CORR did for adults in the angina study. xoma will not, they have better things to do with their money and the resulting drug will be less of a profit one, cause is an smaller indication,less money. I am not questioning you about that, I am asking xoma to do it.